MAGELLAN LONGEVITY
HomeResearchStudy library › Physiological Bases for the Superiority of Apolipoprotein B as a…
Study summary · Cardiovascular & vascular aging

What are the physiological mechanisms that make apolipoprotein B (apoB) a superior marker of cardiovascular risk compared to low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol?

In one paragraph

ApoB Home Test Kit, a review (J Am Heart Assoc 2022, PMID 36216435) — the review explains that LDL particles are typically the primary determinants of cardiovascular risk. No numeric effect size is reported for ApoB Home Test Kit in the source abstract.

Source: J Am Heart Assoc 2022, PMID 36216435 ↗ · Research map · How Magellan grades evidence · evidence confidence: low

J Am Heart Assoc · 2022 · PMID 36216435 · DOI 10.1161/JAHA.122.025858

Plain-English summary written and published by Magellan Longevity · medical review by Gabriel Radu, DO (physiatrist, NPI 1376861765). We summarize what the paper reported — we did not run this study.

The takeaway

ApoB is a better indicator of heart disease risk than LDL-C because it directly measures the number of harmful particles, which is more accurate than measuring only the cholesterol within them.

The question

What are the physiological mechanisms that make apolipoprotein B (apoB) a superior marker of cardiovascular risk compared to low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol?

What they tested

The review posits that specific physiological mechanisms related to the nature, number, and cholesterol content of atherogenic apoB lipoprotein particles explain why apoB is a more accurate marker of cardiovascular risk.

How they did it

This is a narrative review that outlines the physiological mechanisms. It discusses the nature and relative numbers of different apoB particles, the mechanisms governing the number of very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) particles, and the mechanisms governing the cholesterol mass within these particles. It also briefly outlines major apoB dyslipoproteinemias.

What they found

The review explains that LDL particles are typically the primary determinants of cardiovascular risk. It details how concentrations of triglycerides and LDL-C can obscure this relationship. It further clarifies that the total number of apoB particles, except in cases of dysbetalipoproteinemia, determines cardiovascular risk. The review highlights that the discordance between the cholesterol mass within apoB particles (measured as LDL-C or non-HDL-C) and the actual number of apoB particles (measured as apoB) is responsible for apoB's superior predictive power.

What it means

Apolipoprotein B (apoB) is a more accurate marker of cardiovascular risk than LDL-C or non-high-density lipoprotein cholesterol due to specific physiological mechanisms related to the number and cholesterol content of atherogenic apoB lipoprotein particles. This review provides a physiological framework for healthcare providers to understand this superiority.

Limitations

This is a review article and does not present new experimental data or a meta-analysis of existing studies. It focuses on explicating known physiological mechanisms.

“the total number of apoB particles determines cardiovascular risk”— from the published abstract, J Am Heart Assoc 2022

The paper at a glance

TitlePhysiological Bases for the Superiority of Apolipoprotein B as a Marker of Cardiovascular Risk
JournalJ Am Heart Assoc
Year2022
PMID36216435 ↗
DOI10.1161/JAHA.122.025858 ↗
TopicCardiovascular & vascular aging

Read the source: PubMed record (authors, abstract, full citation) ↗ · Publisher via doi.org ↗

Where Magellan uses this paper

This citation sits behind the evidence grade on the pages below. Grades are set from the research and are independent of affiliate commissions.

ApoB Home Test Kit

Large Mendelian randomization studies, prospective cohorts and meta-analyses — in one pooling of 233,455 people apoB was the strongest lipid risk marker, about 12% better than LDL-cholesterol — indicate that apoB is the predominant lipid trait driving atherosclerotic cardiovascular disease, and that the particle…

ApoB Home Test Kit

Apolipoprotein B (apoB) is the primary structural protein of the atherogenic lipoproteins, with exactly…

Check price on Amazon ↗

Research describes the compound or intervention studied. It is not a claim about any specific product.

Molecules & mechanisms in this paper

Each of these is named in the paper’s own words above. Open the monograph for the full mechanism and its other citations.

Cite this page

These citations point at this summary. To cite the original paper with its full author list, use the PubMed record or doi.org.

APA
Magellan Longevity. (2026). What are the physiological mechanisms that make apolipoprotein B (apoB) a superior marker of cardiovascular risk compared to low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol? [Plain-English summary of J Am Heart Assoc 2022, PMID 36216435, DOI 10.1161/JAHA.122.025858]. Magellan Longevity. https://magellanlongevity.com/study/d36216435.html
BibTeX
@misc{magellan_d36216435, title = {What are the physiological mechanisms that make apolipoprotein B (apoB) a superior marker of cardiovascular risk compared to low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol?}, author = {{Magellan Longevity}}, year = {2026}, howpublished = {\url{https://magellanlongevity.com/study/d36216435.html}}, note = {Plain-English summary of PubMed PMID 36216435; DOI 10.1161/JAHA.122.025858; J Am Heart Assoc 2022. Reviewed by Gabriel Radu, DO}, urldate = {2026-08-11} }
Permalink
https://magellanlongevity.com/study/d36216435.html

Related studies in the Magellan library

All 67 Magellan summaries on cardiovascular & vascular aging →

How this summary was made. Every section above restates what the published abstract of PMID 36216435 reports — the question, the design, the numbers, the authors’ own conclusion and their stated limitations. We do not add claims the paper did not make, and we keep negative and no-effect findings in. Magellan’s evidence grades are set from research like this and never from affiliate commissions.

Prefer the interactive version? Open this summary in the Magellan app → · Browse all 314 study summaries →

Educational information, not medical advice. This is a plain-English summary of published research; it is not a treatment recommendation and nothing here is intended to diagnose, treat, cure, or prevent any disease. Individual studies can be wrong, and a single paper rarely settles a question. Talk to your physician before acting on any research, especially if you are pregnant, nursing, or taking medication.